Introduction {#Sec1}
============

Alternative mRNA isoforms have important roles in normal development and physiology. Almost every human gene produces more than one mRNA isoform, vastly expanding the information content of the human genome (Djebali et al. [@CR18]). Alternative and aberrant pre-mRNA splice isoforms also play an important role in cancer. In fact, altered splicing patterns have been suggested as a new "hallmark" of cancer cells, in addition to other well-established hallmarks of cancer such as evasion of cell death and metastasis (Hanahan and Weinberg [@CR26]; Ladomery [@CR31]; Oltean and Bates [@CR54]). Recent data indicate a key role for splicing pattern changes in the pathology of prostate cancer. Alternative splicing programmes in prostate cancer have been the topic of excellent reviews (Hagen and Ladomery [@CR24]; Lu et al. [@CR41]; Nakazawa et al. [@CR52]; Rajan et al. [@CR59]; Sette [@CR64]). Here we particularly concentrate on developments in the last 3 years.

Alternative splicing patterns include whole exons being either spliced in or left out (exon skipping) and alternative utilisation of both 5′ and 3′ splice sites to insert exons of different sizes. Alternative mRNA isoforms can also be generated by the selection of different promoters and different polyadenylation sites. Each of these pathways produces mRNA splice variants that can impact on prostate cancer development or response to treatment (summarised in Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Different kinds of splicing pattern and their effect on prostate cancer cell biology. The most common form of alternative splicing in human cells is shown, with key examples from prostate cancer (not shown, whole introns can also be left in the mRNA)

Prostate cancer is the second most frequent male cancer in the UK, with 47,300 cases being diagnosed in the UK in 2014 (corresponding to 130 new cases diagnosed per day, [http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer\#heading-Zero](http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer%23heading-Zero)). The prostate is a small gland located just below the bladder that produces seminal fluid components. Prostate cancers typically do not cause symptoms, but in some more advanced stages can block urine flow from the bladder, invade the adjacent seminal vesicles and metastasise more distantly to bone. Primary prostate cancer leads to a breakdown in the normal glandular structure of the prostate gland. Prostate cancer is classified histologically by morphological features using the Gleason scoring system (Gleason and Mellinger [@CR23]) (for example, see Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Prostate tissue visualised using tissue biopsies. **a**, **b**. Histological sections made from benign prostatic hyperplasia (BPH, with normal glandular structure embedded in stroma). Prostate cancer development is clinically described as a series of Gleason grades (1--5, with 1 corresponding to well-differentiated tissue containing a glandular structure and 5 being the most advanced with only few glands still visible) (Gleason and Mellinger [@CR23]; Mellinger et al. [@CR44]). **c**, **d** Histological sections made from prostate cancer (Gleason grade 5, notice breakdown of glandular structure). Left panels, sections processed using H&E staining. Right panels, sections processed by staining with haematoxylin and counterstaining with the RNA-binding protein Sam68 (*brown stain*).Figure adapted from (Rajan et al. [@CR57]) with permission from the Journal of Pathology

Alternative splicing of genes under androgen control in prostate cancer {#Sec2}
=======================================================================

Clinical progression of prostate cancer is fuelled by a group of steroid hormones called androgens (Livermore [@CR39]; Mills [@CR45]). Androgens are small hydrophobic molecules that can cross the cell membrane, and include the male hormone testosterone. Once within cells, androgens bind to a nuclear hormone receptor protein called the androgen receptor (AR). The AR typically has a default cytoplasmic location in the absence of androgens, but translocates into the nucleus after binding to androgens via its ligand-binding domain (LBD). Once inside the nucleus, the AR binds to DNA target sequences via its DNA-binding domain (DBD) and controls patterns of downstream gene transcription via its N-terminal TF domain (Fig. [3](#Fig3){ref-type="fig"}a). The AR transcriptionally controls in the order of 700 genes within prostate cancer cells (Munkley et al. [@CR50]).Fig. 3Transcriptional control by **a** the full-length androgen receptor and **b** constitutively active AR isoforms made by splice variants. In (**a**), testosterone enters the prostate cancer cell and becomes modified to dihydroxytestosterone (DHT) by 5α-reductase. DHT binds to the androgen receptor (AR), displacing heat shock protein 90 (HSP) and resulting in AR translocation into the nucleus. Once inside the nucleus, the AR binds to consensus DNA sequence elements called androgen response elements (AREs) to control target gene expression. In (**b**), an androgen receptor variant protein (AR-V) lacking the ligand-binding domain is able to directly translocate into the nucleus without binding to DHT, resulting in androgen-independent control of gene expression

Androgen hormones can affect splicing patterns as well as transcription. Many splicing decisions are made on nascent RNAs while their transcription is still in progress (Kornblihtt [@CR30]). Increased transcriptional speeds from androgen-regulated promoters in the presence of androgens could potentially provide the spliceosome with a choice of exons to include into the mRNA. Consistent with this, transcripts from a *CD44* minigene driven from a steroid-responsive promoter show increased exon skipping in response to the joint presence of the AR and androgens (Rajan et al. [@CR57]). The AR also recruits some RNA-binding proteins as cofactors that can affect splicing. These include the RNA-binding protein Sam68 that decreases skipping of *CD44* variable exons, and the RNA helicase p68 that increases skipping of *CD44* variable exons (Fig. [1](#Fig1){ref-type="fig"}) (Clark et al. [@CR16]; Rajan et al. [@CR57]).

The above experiments used artificial model minigenes to investigate splicing control of AR target genes. Initial searches to find endogenous androgen-dependent splice isoforms used exon microarrays to probe the entire transcriptome (Rajan et al. [@CR60]). These initial experiments identified two endogenous androgen-dependent cassette exons, one in the *ZNF121* gene that encodes a zinc finger-containing protein (this *ZNF121* exon was activated by androgens) and one in the *NDUFV3* gene that encodes a mitochondrial respiratory protein (this *NDUFV3* exon was repressed by androgens). Although these *ZNF121* and *NDUFV3* exons changed splicing in response to androgens, their clinical importance is not known, nor if these genes are direct targets for the AR. However, this same study also identified a number of androgen-dependent mRNAs made from alternative promoters, including an alternative mRNA isoform of the normally tumour suppressor *TSC2* (*Tuberous Sclerosis 2*) gene that is transcribed from an internal promoter (so only contains downstream *TSC2* exons). The well-characterised full-length TSC2 protein represses cell growth via the mTOR pathway. The androgen-driven alternative *TSC2* mRNA isoform encodes a shorter (C-terminal only) TSC2 protein that promotes rather than represses cell growth (Munkley et al. [@CR48]).

More recent RNAseq analysis of prostate cancer cell transcriptomes identified an androgen-regulated and prostate-specific *ST6GALNAC1* mRNA splice isoform. *ST6GALNAC1* encodes the important ST6GalNac1 enzyme that synthesises the cancer-associated sialyl-Tn (sTn) antigen (Munkley et al. [@CR49]). In prostate cancer cells, an alternative spliced *ST6GALNAC1* mRNA isoform that encodes a shorter ST6GalNac1 protein isoform is made. This shorter ST6GalNac1 protein isoform is actually made from a longer mRNA, since an extra exon is included within the 5′ untranslated region (UTR) of the *ST6GALNAC1* mRNA in the prostate. The presence of this extra exon causes an alternative start codon to be utilised, resulting in the shorter version of the ST6GalNac1 protein (Munkley et al. [@CR49]). This shorter ST6GalNac1 protein is produced at higher levels in prostate cancer cells than the previously reported full-length protein; yet it is able to synthesise the sTn antigen which is linked to patient survival and metastasis, and controls cell adhesion (Munkley et al. [@CR49]). The changed 5′ UTR structure of the prostate-specific mRNA isoform of ST6GalNac1 might even enhance its translation, resulting in increased ST6GalNAc1 enzyme levels and more synthesis of sTn antigen (Munkley [@CR47]). Both the short and long isoforms of ST6GalNac1 use the same androgen-driven promoter, but the 5′ UTR exon-skipped isoform has only been reported thus far in the prostate.

Alternative splicing patterns of an androgen-regulated oncogenic fusion gene called *ETS*-*related gene* (*ERG*) are associated with more advanced forms of prostate cancer progression. *ERG* is a proto-oncogene that plays a key role in the pathology of prostate cancer. *ERG* encodes a transcription factor that controls the expression of many genes during normal development (Adamo and Ladomery [@CR2]). *ERG* is not normally transcriptionally controlled by androgens, but gene fusions can place *ERG* under transcriptional control by the androgen-regulated *TMPRSS2* gene on the transition between prostatic epithelial neoplasia to prostate carcinoma. Such genetic rearrangements frequently link exon 1 or exons 1 and 2 of the *TMPRSS2* gene, and the upstream *TMPRSS2* gene promoter, to exon 4 and downstream regions of the *ERG* gene, by removing intervening regions of chromosome 21.

The *TMPRSS2*--*ERG* fusion gene is one of the most frequently over-expressed genes in prostate cancer. The encoded TMPRSS2--ERG fusion protein controls many important properties of prostate cancer cells, including cytoskeletal organisation, cell proliferation, expression of prostate-specific antigen (abbreviated PSA; this is a key serum biomarker for detecting prostate cancer) and epithelial--mesenchymal transitions (EMT) crucial for prostate cancer cell metastasis (Adamo and Ladomery [@CR2]). Reverse transcription PCR (RT-PCR) analyses of tumour mRNA from patients show that more clinically advanced prostate cancers with histological evidence for seminal gland invasion have decreased skipping of two cassette exons within the *ERG* gene, compared with more localised prostate cancers and benign prostate tissue (Hagen et al. [@CR25]). Increased splicing inclusion of these two *ERG* exons might contribute to the production of more oncogenic isoforms of the ERG fusion protein. One of these alternatively spliced *ERG* exons (of 72 nucleotides in length) encodes an in-frame peptide sequence. Inclusion of this 72-nucleotide exon might affect the interactions of the encoded ERG protein with transcription factors and other nuclear proteins, since it is immediately adjacent to the region of the *ETS* gene that encodes a protein--protein interaction domain called the sterile alpha motif (SAM)/pointed domain (<http://pfam.xfam.org/family/SAM_PNT>).

Changes in *AR* mRNA splicing patterns enable prostate cancer cells to become hormone resistant {#Sec3}
===============================================================================================

The primary therapeutic strategy for advanced prostate cancer treatment is to block androgen signalling through androgen deprivation therapy or AR blockade, thereby halting tumour progression. Abiraterone is a drug that inhibits androgen biosynthesis and so reduces the levels of androgens within prostate cancer cells. Enzalutamide is a drug that antagonises the interaction of androgens with AR protein. Although prostate tumours initially respond to androgen deprivation therapy, later stages of the disease can develop into a treatment-resistant form of the disease called castration-resistant prostate cancer. Mechanisms of prostate cancer cell resistance cross over, so a prostate cancer cell developing resistance to enzalutamide will also show a reduced (\~20%) response to abiraterone, and vice versa (Liu et al. [@CR38]).

Changing patterns of *AR* pre-mRNA splicing play a critical role in enabling prostate cancer cells to develop castration resistance. Changed splicing patterns generate variant AR protein isoforms (abbreviated AR-V) that lack ligand-binding domains, frequently as a result of splicing inclusion of cryptic exons (abbreviated CE), making them independent of androgen control. Some AR-V protein variants translocate into the nucleus even in the presence of enzalutamide (Fig. [3](#Fig3){ref-type="fig"}). *AR* pre-mRNA splicing changes thus enable prostate cancer cells to proliferate during androgen deprivation therapy in reduced circulating androgen concentrations.

Around 20 *AR* variant splice isoforms have been implicated in the development of hormone refractory prostate cancer \[reviewed by Lu and Luo ([@CR40])\]. The clinically most frequent *AR* splice variant, called *ARv7*, is produced by splicing inclusion of a cryptic exon called CE3 located within intron 3 (Fig. [4](#Fig4){ref-type="fig"}). *AR* CE3 is a terminal exon, meaning that splicing inclusion is linked to the selection of a new poly(A) site, thus creating a truncated *AR* mRNA that lacks coding information for the Ligand-Binding Domain (abbreviated LBD). As a result, *ARv7* encodes a short yet constitutively active isoform of the AR (active in the absence of androgens). While full-length AR protein is dependent on androgen binding via its LBD to translocate into the nucleus and control transcriptional activity, ARv7 protein is constitutively present in the nucleus even in the absence of androgens and so can provide AR activity in androgen-depleted prostate cancer cells (Cao et al. [@CR14]). Expression of ARv7 is important for prostate cancer cell growth: siRNA-mediated depletion of ARv7 (using siRNAs complementary to CE3) inhibits the growth of the VCaP cell line in androgen-limiting conditions (Liu et al. [@CR36]).Fig. 4Exon--intron organisation of the *AR* gene and frequent pathogenic *AR* mRNA splice isoforms. **a** The AR protein is encoded by the 8-exon *AR* gene on the X chromosome. The full-length AR mRNA is made by splicing of exons 1--8. ARv7 mRNA is made by splicing cryptic exon 3 (CE3) after exons 1--3. Splicing of CE3 is associated with transcriptional termination, so this makes a truncated mRNA and truncated AR protein (aberrant splicing pathway shown above the AR gene). ARv567 is made by skipping of exons 5--7 in the *AR* mRNA (aberrant splicing pathway shown below the AR gene). Exons 1--8 are spliced together to produce the canonical *AR* splice isoform that encodes a full-length AR protein isoform. Aberrant splicing patterns include splicing of exon 3 to cryptic exon CE3, which is linked to premature termination of transcription (using an intron 3-internal polyA site) and a truncated mRNA, and skipping of exons 5--7. **b** Both full-length and AR variants are translated from different mRNA isoforms. Full-length AR protein contains an N-terminal domain (important for transcriptional activation) encoded by exon 1, a C4-type zinc finger DNA-binding domain encoded by exons 2--3 and a ligand-binding domain (which binds to androgens) encoded by exons 4--8. ARv7 is lacking the ligand-binding domain. ARv567es is lacking most of the ligand-binding domain

Supporting ARv7 protein or RNA expression being a potentially useful biomarker for disease progression, AR variant splice isoform levels change during prostate cancer development. Expression levels of ARv7 mRNA in patients with prostate cancer predict their pharmacological response to enzalutamide and abiraterone (Antonarakis et al. [@CR6]). Levels of nuclear Arv7 protein can also be monitored by immunohistochemistry using a monoclonal antibody and are predictive of overall survival (Welti et al. [@CR75]). Prostate cancer cells metastasise to bone via circulating tumour cells which are released from the primary tumour. Single-cell RNAseq analysis of circulating tumour cells purified from the bloodstream identified *AR* splice variants in most (8 out of 11 sequenced) patients, but less frequently in primary tumours (Miyamoto et al. [@CR46]). Consistent with *ARv7* expression being an adaptive response of cells to reduced androgen levels, *ARv7* splice isoform levels increase in response to androgen deprivation therapy and decrease on the reintroduction of androgens (Yu et al. [@CR76]). Expression of *ARv7* is controlled by the transcription factors Myc (Myc also controls the expression of full-length *AR*) and NFκβ2, both of which increase expression in prostate cancer (Nadiminty et al. [@CR51]).

Rather than providing a like-for-like replacement with the full-length androgen receptor, ARv7 protein instead preferentially regulates the expression of genes involved in active cell division and so promotes cell division rather than differentiation (Hu et al. [@CR28]; Nakazawa et al. [@CR52]). ARv7 expression in the LNCaP prostate cancer cell line also changes patterns of cell metabolism, decreasing the production of citrate and increasing the breakdown of glutamine---features of the "Warburg effect" changes in cancer metabolism that are also observed in prostate tumours (Shafi et al. [@CR65]).

*ARv567es* is a further cancer-associated *AR* splice form observed in patients and also encodes a constitutively active AR protein (Fig. [4](#Fig4){ref-type="fig"}). *ARv567es* mRNA is made through skipping of exons 5--7 of the *AR* pre-mRNA and is only expressed within prostate cancer (and not the normal prostate). The ARv567es protein isoform regulates the transcription of genes involved in cell cycle control and particularly activates the expression of the oncogene *UBE2C*. UBE2C is a ubiquitin-conjugating protein active during mitosis, as part of the anaphase-promoting complex (APC) that inactivates the mitotic checkpoint control. UBE2C protein is highly expressed in solid tumours and promotes cell proliferation. Transcriptional activation by the ARv567es AR isoform occurs via a DNA looping mechanism that involves interaction with the transcription factor MED1 (part of the mediator complex involved in transcriptional initiation), and within castration-resistant but not hormone-responsive prostate cancer (Liu et al. [@CR37]). In mice, the expression of AR variant isoforms can be sufficient themselves to induce cancer development. Transgenic mouse models expressing ARv567es and ARv7 proteins within their prostate glands develop prostate cancer (Liu et al. [@CR34]; Sun et al. [@CR69]).

AR splice variants and the pathways that generate them are therapeutic targets in prostate cancer {#Sec4}
=================================================================================================

The clinical importance of aberrant *AR* splice isoforms has generated a lot of interest in their generation. A good model for investigating this is the 22Rv1 prostate cancer cell line, which expresses ARv7 protein as well as full-length AR protein. Depletion of ARv7 is sufficient to sensitise 22Rv1 cells to abiraterone (Liu et al. [@CR38]). A genomic deletion removes 48 nucleotides of intron 1 from the *AR* gene within 22Rv1 cells. This genomic deletion might contribute to altered splicing patterns of CE3, through changing intronic binding sites available for splicing regulator proteins (Li et al. [@CR32]).

Androgen deprivation therapy results in increased binding of SRSF1 and U2AF65 near the 3′ splice site of cryptic CE3, although the levels of these splicing regulator proteins themselves do not change in response to androgen deprivation (Liu et al. [@CR36]). However, the expression levels of *U2AF2* (the gene which encodes U2AF65) do increase in hormone-resistant prostate cancer compared to primary prostate cancer (Stockley et al. [@CR67]). Expression levels of the splicing regulator Sam68 protein also increase in prostate cancer (Busa et al. [@CR13]; Rajan et al. [@CR57]) and can drive *AR* CE3 splicing inclusion (Stockley et al. [@CR67]). ARv7 splicing production is also stimulated by the expression of the splicing regulator hnRNPA1 (Nadiminty et al. [@CR51]). This is particularly important, since the levels of hnRNPA1 increase in prostate cancer, and hnRNPA1 expression has been observed as an early marker for tumour development in several cancers. Genomic rearrangements including intron sequences also occur in situ within prostate cancers expressing *AR* mRNA splice variants, although the major factor leading to the expression of AR splice variants is the corresponding increased expression levels of the full-length *AR* isoform (Henzler et al. [@CR27]).

It is hoped that understanding the splicing pathways generating *AR* splice variants will lead to downstream clinical applications used to treat prostate cancer. Supporting this idea, siRNA-mediated depletion of hnRNA1 re-sensitises a cell line model of castration-resistant prostate cancer to enzalutamide (Nadiminty et al. [@CR51]). Thus, the connection between hnRNPA1 expression and splicing pathways producing *ARv7* might prove to be clinically relevant. Interestingly, increased levels of the RNA-binding protein Lin28 also correlate with increased *ARv7* expression. Down-regulation of Lin28 sensitises prostate cancer cells to enzalutamide. Lin28 expression increases in prostate cancer and regulates the expression of *Let7* family microRNAs that operate upstream of Myc and a number of splicing factors including hnRNPA1 that in turn control *ARv7* production (Tummala et al. [@CR73], [@CR74]).

Small-molecule inhibitors might be used to block splicing pathways leading to *ARv7* production. One such small molecule is Onalespib, which inhibits the heat shock protein HSP90. Ordinarily, translocation of full-length AR protein into the nucleus following androgen stimulation is achieved via interactions with HSP90 (Fig. [3](#Fig3){ref-type="fig"}a). Onalespib does not affect the splicing pathway generating the full-length AR protein isoform (although full-length AR protein stability is decreased by Onalespib). Onalespib does inhibit the splicing pathways that generate the ARv7 splice isoform (in addition to \>500 other splice isoforms) (Ferraldeschi et al. [@CR21]). In an in vivo model, Onalespib treatment also increases survival of nude mice xenografted with the ARv7-expressing 22Rv1 cell line. Mechanistically, HSP90 inhibition in prostate cancer cells might affect signalling pathways operating upstream of SR proteins like SRSF1 that are involved in *AR* CE3 splicing inclusion (possibly including effects on the protein kinase SRPK1, see below). However, it is worth noting that other HSP90 inhibitors have been reported to have different effects on *ARv7* splice isoform variant production (Gillis et al. [@CR22]; Shafi et al. [@CR65]).

Alternative splicing patterns could help guide the development of personalised therapies for prostate cancer patients (Anand and Bjartell [@CR5]; Antonarakis et al. [@CR6]; Palapattu [@CR56]; Savage [@CR62]; Sun and Abdollah [@CR68]; Taneja [@CR71]). Since the production of ARv7 is predictive of abiraterone and enzalutamide sensitivity in advanced prostate cancer, this may guide treatment options towards selection of other drug regimes that should be used instead. Such drugs include taxanes (which inhibit microtubule function) and galeterone (targets the AR for degradation, as well as blocking binding of androgens) (Antonarakis et al. [@CR6], [@CR7]; Onstenk et al. [@CR55]; Savage [@CR62]; Thadani-Mulero et al. [@CR72]). An FDA-approved drug called niclosamide, originally developed against helminths, strongly targets ARv7 and restores susceptibility of prostate cancer cells to abiraterone, both in vitro and by oral administration into nude mice with 22Rv1 cell line xenografts (Liu et al. [@CR35], [@CR38]).

Splicing regulators can change expression patterns in prostate cancer {#Sec5}
=====================================================================

A number of splicing regulator proteins change expression patterns in prostate cancer, including in neuroendocrine prostate cancer. Neuroendocrine prostate cancer is an aggressive form of prostate cancer thought to result from trans-differentiation of castration-resistant prostate cancer cells into cells harbouring a neuroendocrine phenotype. This transition occurs at low androgen conditions. Neuroendocrine prostate cancer does not respond to AR-directed therapies. Recent data indicate that the development of neuroendocrine prostate cancer is driven by an increased expression of the splicing factor SRRM4 (serine/arginine repetitive matrix 4 protein). SRRM4 is a splicing factor normally needed in the body (outside of the prostate gland) for neural differentiation. SRRM4 up-regulation drives splicing switches towards neuronal splicing patterns and the trans-differentiation of prostate cells towards neuroendocrine prostate cancer cells (Li et al. [@CR33]; Zhang et al. [@CR77]). Important SRRM4-regulated events include a splicing switch in the transcription factor REST1 (RE1 silencing transcription factor) which is a master regulator of neurogenesis, thus providing a possible molecular explanation for the neuroendocrine prostate cancer phenotype (Li et al. [@CR33]).

The KH domain-containing protein Sam68 is also up-regulated in prostate cancer (Busa et al. [@CR13]; Rajan et al. [@CR57]). Sam68 interacts with RNA via its STAR domain \[comprising a KH domain and flanking protein sequences (Feracci et al. [@CR20])\]. Sam68 regulates splicing of the *CD44* mRNA (controlling the production of splice isoforms important in metastasis), *BCLx* (controlling splice isoforms important in cell death via apoptosis) and *CCND1* (controlling splice isoforms important in the cell cycle) \[Fig. [1](#Fig1){ref-type="fig"}, and reviewed by (Sette [@CR64])\]. Recent work shows that Sam68 protein interacts with the transcriptional co-activator protein SND1, to switch splicing of *CD44* pre-mRNA towards the production of more metastasis-associated splice isoforms \[including *CD44* exon v5 (Cappellari et al. [@CR15])\]. Levels of both SND1 and Sam68 protein increase in prostate cancer cells. Sam68 also interacts with the transcription factor FBI-1 to control *BCLx* splicing patterns, with FBI-1 inhibiting the production of the apoptotic BCLx isoform (Bielli et al. [@CR10]). Sam68 protein additionally interacts with the RNA splicing regulator hnRNPA2/B1, which is also up-regulated in prostate cancer, and controls the expression of β-catenin (Rajan et al. [@CR58]; Stockley et al. [@CR66]).

The splicing regulator protein Tra2β also increases the expression in prostate cancer tissues, and this is associated with preoperative prostate-specific antigen, lymph node metastasis, clinical stage, Gleason score and biochemical recurrence (Diao et al. [@CR17]). Global studies carried out in breast cancer cells discovered *CHK1* exon 3 as an important splicing target for Tra2β (Best et al. [@CR8]). CHK1 is a key checkpoint protein that monitors DNA integrity after replication stress. Interestingly, joint depletion of Tra2β and its ortholog Tra2α inhibits *CHK1* exon 3 splicing in the LNCaP prostate cancer cell line (Best et al. [@CR8]). Since *CHK1* exon 3 is not a multiple of 3, this skipping event leads to loss of function, accumulation of DNA damage and cell death.

Another splicing regulator that changes expression in prostate cancer is the protein kinase SRPK1. SRPK1 does not itself bind to pre-mRNA directly, but instead phosphorylates members of the important SR family of splicing regulators, including SRSF1. SRSF1 is a critical splicing regulator in the cell, and phosphorylation by SRPK1 enables SRSF1 nuclear localisation. Once in the nucleus, SRSF1 controls splicing of *VEGF* (vascular epithelial growth factor) mRNA which is important for angiogenesis. SRSF1 switches *VEGF* splicing patterns between pro- and anti-angiogenic mRNA splice isoforms via selection of an alternative 3′ splice site (Fig. [1](#Fig1){ref-type="fig"}) (Amin et al. [@CR4]). SRPK1 is a promising target for therapy. SRPK1 inhibition keeps SRSF1 in the cytoplasm and, as a result, decreases the ability of the prostate cancer cell line PC-3 to form tumours in mouse xenografts, probably through changed patterns of *VEGF* mRNA splicing depriving prostate cancer cells from developing a blood supply (Mavrou et al. [@CR43]). SRPK1 expression increases in prostate cancer (Bullock and Oltean [@CR11]; Bullock et al. [@CR12]; Mavrou et al. [@CR43]). Existing drugs are available that can target SRPK1 and have already been tested in mouse models (Mavrou et al. [@CR43]; Mavrou and Oltean [@CR42]). A further important kinase that might impact on prostate cancer pathology is aurora A, which affects the production of *ARv* splice variants, likely also through control of SRSF1 (Jones et al. [@CR29]).

Current developments {#Sec6}
====================

Investigation of splicing in prostate cancer is currently undergoing methodological change with the incorporation of analysis from big data sets, particularly with the global discovery of new splice isoforms. Future research in this area is likely to include comparison of large "-omics" level datasets to detect many splice isoform changes between different grades of prostate cancer tissue in parallel. Already, RNAseq datasets from patients with prostate cancer are available on sites like The Cancer Genome Atlas (TCGA, <https://portal.gdc.cancer.gov/>) and the International Cancer Genome Consortia (ICGC, <http://icgc.org/>). Increased understanding of mRNA splice isoforms in prostate cancer will also come from integrating RNAseq data with peptide data from mass spectroscopy, thus enabling direct correlation of alternative isoforms and their encoded proteins (Evans et al. [@CR19]; Nesvizhskii [@CR53]). Individual splice isoform functions can be dissected to assess their importance in disease pathology, and whether they might be useful targets for therapeutic intervention or as prognostic markers (in a similar way in which the AR splice variants have been investigated).

Integrating data from system-wide approaches will also be helpful for understanding how these splice isoforms are generated in prostate cancer cells. Transcriptome-wide binding maps of RNA splicing regulator proteins in cancer cells can be used to identify splicing targets important for therapy and diagnostics (Best et al. [@CR8]; Sundararaman et al. [@CR70]). The expression patterns of these RNA splicing regulators themselves can also be globally analysed through transcriptome data, and at the genome level how these expression levels are impacted by copy number variation patterns of their genes (Sebestyen et al. [@CR63]). Since splicing takes place co-transcriptionally on nascent pre-mRNAs, other contributors to alternative splicing patterns to be investigated in prostate cancer cells will be chromatin components and epigenetic marks (Allemand et al. [@CR3]). These features might be particularly important also to functions of the AR in both prostate cancer pathology and generation of alternative splice isoforms (Rajan et al. [@CR59], [@CR60]).

Summary {#Sec7}
=======

Although research in this area has been very productive, still remaining open in this field is a full understanding of how alternative splicing programmes impact on prostate cancer pathology. Research in the past few years shows that splicing patterns change during prostate cancer progression and in response to therapeutic intervention. Some splicing changes enable prostate cancer cells to grow in limiting concentrations of androgens, and some cause the production of more oncogenic proteins contributing to disease pathology. Understanding these splicing changes, and the mechanisms driving them, opens up new possibilities for developing diagnostic and therapeutic strategies to treat prostate cancer. As a result of these investigations, future therapies might aim to target specific splice isoforms, for example using antisense oligonucleotide and morpholino techniques that have been developed for other diseases including Duchenne muscular dystrophy and spinal muscular atrophy (Aartsma-Rus and Krieg [@CR1]; Rigo et al. [@CR61]). For example, blocking splicing of exon 3 of *CHK1* mRNA might specifically kill cancer cells that rely on *CHK1* in the absence of other checkpoints to control replication stress (Best et al. [@CR8], [@CR9]).
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